A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
NCT02649218
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
226
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Spontaneous Urticaria
Interventions
BIOLOGICAL:
Ligelizumab
Sponsor
Novartis Pharmaceuticals